Sandoz Will Steer Clear Of U.S. Biosimilars Pathway, Use Other Applications
Executive Summary
Drug companies looking to bring biosimilars to the U.S. market will use existing regulatory pathways like 505(b)(2) or an outright Biologics Licensing Application over a new regulatory pathway provided in the health care reform legislation because of provisions in the new pathway that favor brands, Jeff George, the head of Sandoz, predicted
You may also be interested in...
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28
FOBs: Industry Begins To Plot Course Along Pathway As It Awaits FDA Policy
Everyone in the drug industry is eagerly waiting for any sign from FDA as to how it will handle biosimilar applications. So a recent meeting with a session devoted to FDA's current position on follow-on biologics was particularly tantalizing